Phase I trial of taxotere : five-day schedulePAZDUR, R; NEWMAN, R. A; RABER, M. N et al.Journal of the National Cancer Institute. 1992, Vol 84, Num 23, pp 1781-1788, issn 0027-8874Article

Effects of taxotere on murine and human tumor cell linesRIOU, J.-F; NAUDIN, A; LAVELLE, F et al.Biochemical and biophysical research communications (Print). 1992, Vol 187, Num 1, pp 164-170, issn 0006-291XArticle

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells : comparison with taxol and conventional antineoplastic agentsVOGEL, M; HILSENBECK, S. G; HANAUSKE, A.-R et al.European journal of cancer. Part A. 1993, Vol 29, Num 14, pp 2009-2014Article

Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusionEXTRA, J.-M; ROUSSEAU, F; BRUNO, R et al.Cancer research (Baltimore). 1993, Vol 53, Num 5, pp 1037-1042, issn 0008-5472Article

Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patientMENCOBONI, M; OLIVIERI, R; VANNOZZI, M. O et al.Chemotherapy (Basel). 2006, Vol 52, Num 3, pp 147-150, issn 0009-3157, 4 p.Article

3,3'-Diindolylmethane enhances Taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1AHMAD, Aamir; ALI, Shadan; ZHIWEI WANG et al.International journal of cancer (Print). 2011, Vol 129, Num 7, pp 1781-1791, issn 0020-7136, 11 p.Article

All-trans retinoic acid potentiates Taxotere-induced cell death mediated by jun N-terminal kinase in breast cancer cellsQIN WANG; WIEDER, Robert.Oncogene (Basingstoke). 2004, Vol 23, Num 2, pp 426-433, issn 0950-9232, 8 p.Article

In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol®) and cisplatin against human tumor and normal bone marrow cellsBRAAKHUIS, B. J. M; HILL, B. T; DIETEL, M et al.Anticancer research. 1994, Vol 14, Num 1A, pp 205-208, issn 0250-7005Article

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancerJUNG HYE KWON; JUNG HAN KIM; PARK, Young-Iee et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 5, pp 889-897, issn 0344-5704, 9 p.Article

Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cellsDANDEKAR, Devendra S; LOPEZ, Monica; CAREY, Robert I et al.International journal of cancer. 2005, Vol 115, Num 3, pp 484-492, issn 0020-7136, 9 p.Article

Hydrophobic collapse of taxol and taxotere solution conformations in mixtures of water and organic solventVANDER VELDE, D. G; GEORG, G. I; GRUNEWALD, G. L et al.Journal of the American Chemical Society. 1993, Vol 115, Num 24, pp 11650-11651, issn 0002-7863Article

Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer : A randomized phase II study. CommentaryFOSSA, Sophie D; JACOBSEN, Anne-Birgitte; BRACARDA, Sergio et al.European urology. 2007, Vol 52, Num 6, pp 1691-1699, issn 0302-2838, 9 p.Article

Docetaxel administration schedule : From fever to tears? A review of randomised studiesENGELS, Frederike K; VERWEIJ, Jaap.European journal of cancer (1990). 2005, Vol 41, Num 8, pp 1117-1126, issn 0959-8049, 10 p.Article

No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assayMAEDA, Shingo; SAIKAWA, Yoshiro; KUBOTA, Tetsuro et al.Anticancer research. 2003, Vol 23, Num 4, pp 3147-3150, issn 0250-7005, 4 p.Article

In vitro cytotoxic activity of Taxol® and Taxotere on primary cultures and established cell lines of human ovarian cancerSILVESTRINI, R; ZAFFARONI, N; ORLANDI, L et al.Stem cells (Dayton, OH). 1993, Vol 11, Num 6, pp 528-535, issn 1066-5099Article

PRECLINICAL AND PILOT CLINICAL STUDIES OF DOCETAXEL CHEMORADIATION FOR STAGE III NON―SMALL-CELL LUNG CANCERCHEN, Yuhchyau; PANDYA, Kishan J; JOHNSTONE, David W et al.International journal of radiation oncology, biology, physics. 2011, Vol 80, Num 5, pp 1358-1364, issn 0360-3016, 7 p.Article

Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer : A phase II study of the Gruppo Oncologico dell' Italia Meridionale (GOIM)GIULIANI, F; ROMITO, S; MAIELLO, E et al.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 14, pp 107-112, issn 1359-6349, 6 p.Conference Paper

Selective drug resistant human osteosarcoma cell linesBURNS, Bennett S; EDIN, Matthew L; LESTER, Gayle E et al.Clinical orthopaedics and related research. 2001, Num 383, pp 259-267, issn 0009-921XConference Paper

Specific approaches (intracavitary chemotherapy) and new agents in the treatment of advanced ovarian cancer = Chimiothérapie intrapéritonéale et nouveaux agents dans le traitement des cancers avancés de l'ovaireVERMORKEN, J. B.Pathologie et biologie. 1994, Vol 42, Num 1, pp 26-27, issn 0369-8114Conference Paper

Le Taxotère : des aiguilles d'if à la clinique = Taxotere: from yew's needles to patientsLAVELLE, F; GUERITTE-VOEGELEIN, F; GUENARD, D et al.Bulletin du cancer. 1993, Vol 80, Num 4, pp 326-338, issn 0007-4551Article

Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticlesZHIGALTSEV, Igor V; WINTERS, Geoff; HELLER, Lindsay et al.Journal of controlled release. 2010, Vol 144, Num 3, pp 332-340, issn 0168-3659, 9 p.Article

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistanceCLEATOR, Susan; TSIMELZON, Anna; CHANG, Jenny C et al.Breast cancer research and treatment. 2006, Vol 95, Num 3, pp 229-233, issn 0167-6806, 5 p.Article

Cystic maculopathy with normal capillary permeability secondary to docetaxelTEITELBAUM, Bruce A; TRESLEY, David J.Optometry and vision science. 2003, Vol 80, Num 4, pp 277-279, issn 1040-5488, 3 p.Article

Thermodynamics of ligand-induced assembly of tubulinDIAZ, J. F; MENENDEZ, M; ANDREU, J. M et al.Biochemistry (Easton). 1993, Vol 32, Num 38, pp 10067-10077, issn 0006-2960Article

Page / 4